



Image  
v

Attorney Docket No.: 6169.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Liselotte Bjerre Knudsen

Application No.: 09/800,541

Group Art Unit: To be assigned

Filed: March 7, 2001

Examiner: To be assigned

Confirmation No. 4130

For: Lowering Serum Lipids

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. WO 99/62872
2. WO 98/05331
3. Young et al., Diabetes, (1999), Vol. 48, pages 1026-1034

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

This information disclosure statement is being filed after the period set forth in 37 C.F.R. 1.97(b), but before the mailing date of any of a final action, a notice of allowance, or an action that otherwise closes prosecution. The Examiner is hereby authorized to Charge Deposit Account No. 14-1447 in the amount of \$180.00. A duplicate of this charge directive is attached.

Respectfully submitted,

*Richard W. Bork*  
Richard W. Bork, Reg. No. 36,459  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800

Date: October 9, 2003

23650  
PATENT TRADEMARK OFFICE



Attorney Docket No.: 6169.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Liselotte Bjerre Knudsen

Serial No.: 09/800,541

Group Art Unit: To be assigned

Filed: March 7, 2001

Examiner: To be assigned

Confirmation No. 4130

For: Lowering Serum Lipids

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Supplemental Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope  
addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on October 9, 2003

Rashida Haji  
(name of person mailing paper)

Rashida Haji  
(signature of person mailing paper)



14 2003		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Atty. Docket No. 6169.200-US		Serial No. 09/800,541	
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant <b>Liselotte Bjerre Knudsen</b>			
		(Use several sheets if necessary)		Filing Date <b>March 7, 2001</b>		Group <b>T</b> be assigned	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<b>FOREIGN PATENT DOCUMENTS</b>							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
	99/62872	12-9-99	WO			YES	NO
	98/05331	2-12-98	WO				
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
EXAMINER	1	Young et al., Diabetes, (1999), Vol. 48, pages 1026-1034					
EXAMINER		DATE CONSIDERED					
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.